• <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
      <b id="1ykh9"><small id="1ykh9"></small></b>
    1. <b id="1ykh9"></b>

      1. <button id="1ykh9"></button>
        <video id="1ykh9"></video>
      2. west china medical publishers
        Keyword
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Keyword "毒副作用" 3 results
        • Advances in the study of local radiotherapy for driver gene-negative oligometastatic non-small cell lung cancer

          Advanced driver gene-negative non-small cell lung cancer is generally considered incurable, and treatment aims to prolong patient survival. Recently, however, a new definition “oligometastasis” has been proposed, which refers to the appearance of no more than 5 metastatic lesions in up to 3 different organs. The emergence of this concept has changed the traditional treatment model. Many studies have shown that standard systemic therapy combined with local therapy (radiotherapy, surgery, thermal ablation, etc.) can effectively prolong the survival time of these patients. This article reviews the clinical studies on the efficacy, toxicity, and beneficiary population of local radiotherapy combined with systemic therapy in driver gene-negative oligometastatic non-small cell lung cancer, and provides further reference for clinical decision-making.

          Release date:2025-04-27 01:50 Export PDF Favorites Scan
        • Observation and Analysis of Toxic and Side Effect of Continuous Hyperthermic Peritoneal Perfusion Chemotherapy

          Objective To observe the toxic and side effects during the continuous hyperthermic peritoneal perfusion chemotherapy (CHPPC).Methods Abdominal paracentesis and catheterization were performed under ultrasound guidance, then CHPPC was carried out, which was in temperature of 42-44 ℃ for 1 h. The changes of body temperature, heart rate, blood pressure, saturation of blood oxygen and respiratory frequency were recorded in 109 patients during and after perfusion, meanwhile symptoms and physical signs of abdominal region and system status such as abdominal tenderness, rebound tenderness were observed. Results There were no significant differences of body temperature, heart rate, blood pressure, saturation of blood oxygen or respiratory frequency between before and after perfusion (Pgt;0.05). There were 25 patients with abdominal pain, but in which only 3 patients with symptoms of acute abdomen, 26 patients with gastrointestinal symptoms, 20 patients with myelosuppression, and others (22 cases) with aches of puncture position which were released by symptomatic treatment. Conclusion There are less toxic and side effect and better tolerance in patients with CHPPC application 1 month after operation.

          Release date:2016-09-08 04:26 Export PDF Favorites Scan
        • 替吉奧聯合奧沙利鉑治療晚期結直腸癌的臨床觀察

          目的評價替吉奧膠囊聯合奧沙利鉑治療晚期結直腸癌患者的近期療效和不良反應。 方法回顧性分析2010年8月-2012年12月64例晚期結直腸癌患者資料,32例采用替吉奧聯合奧沙利鉑(L-OHP)方案化學療法(替吉奧組),32例采用氟尿嘧啶聯合奧沙利鉑(FOLFOX)方案化學療法(氟尿嘧啶組),2周期后評價兩組療效及不良反應。 結果替吉奧組和氟尿嘧啶組總有效率分別為50.0%和46.9%,兩組差異無統計學意義(χ2=0.063,P=0.802);兩組骨髓抑制及胃腸道反應發生率相近,但靜脈炎的發生率替吉奧組明顯低于氟尿嘧啶組(0.0%、9.4%,P<0.05)。 結論替吉奧膠囊聯合奧沙利鉑治療晚期結直腸癌,近期療效較好,不良反應較輕。

          Release date: Export PDF Favorites Scan
        1 pages Previous 1 Next

        Format

        Content

      3. <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
          <b id="1ykh9"><small id="1ykh9"></small></b>
        1. <b id="1ykh9"></b>

          1. <button id="1ykh9"></button>
            <video id="1ykh9"></video>
          2. 射丝袜